NEWS: New treatment option approved for life-threatening liver diseasefor which medicines are urgently needed. The complications of chronichepatitis B kill 1 in 4 of those affected.
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2,contact information and more available athttp://www.prnewswire.com/broadcast/34016/press.shtml
STORY SUMMARY: The FDA has approved Viread(R) (tenofovir disoproxilfumarate) as a treatment option for adults with chronic hepatitis B, a seriousliver disease. Chronic hepatitis B affects an estimated 2 million people inthe United States and is the leading cause of liver cancer worldwide.
Caused by the hepatitis B virus (HBV), a pathogen that is up to 100 timesmore infectious than the AIDS virus, chronic hepatitis B disproportionatelyaffects Asian Americans, who represent nearly half of all cases and are one ofthe fastest-growing population groups in the country.
Because chronic HBV infection can persist for years without causingnoticeable symptoms, the disease is known as a "silent killer" and many peopleare unaware they are infected. New treatment options are urgently needed -- 1in 4 people with the disease ultimately die from serious complications such aschronic liver disease, cirrhosis or liver cancer.
Viread is taken as a once-daily tablet, and works by blocking the enzymethat is necessary for the hepatitis B virus to replicate in liver cells.Viread has been available in the United States as a part of combinationtherapy for HIV infection since 2001, and its active ingredient is themost-prescribed compound in HIV therapy.
To learn more about VIREAD, including box warnings, important safetyinformation and full prescribing information, please visit www.Viread.com.
-- Fred Poordad, MD / Chief of Hepatology, Cedars-Sinai Center for LiverDisease and Transplantation, Los Angeles
-- Danny Chu, MD / Community Physician, Chinatown, New York City
-- Fiona Ma / Hepatitis B patient, California Assemblywoman, San Francisco
B-ROLL INCLUDES: Viread packaging and manufacturing** Doctor/patient**Gilead campus**Leading Cause of Liver Cancer Affects 2 Million People in United States SATELLITE FEEDS: Monday, August 11th, 2008 Tuesday, August 12th, 2008 7:30 PM - 7:45 PM ET 3:00 AM - 3:15 AM ET Galaxy 28 Galaxy 28 Transponder 15 Transponder 15 C-Band C-Band Downlink Freq: 4000 Vertical Downlink Freq: 4000 Vertical Tuesday, August 12th, 2008 1:00 PM - 1:15 PM ET AMC 3 Transponder 19 C-Band Downlink Freq: 4080 Horizontal
SOURCE Gilead Sciences